Article
Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Jun 2017
Zheng Zhen, Xie Deyao, Su Huafang, Lin Baochai, Zhao Lihao, Deng Xia, Chen Hanbin, Fei Shaoran, Jin Xiance, Xie Congying
Abstract excerpt
Recent studies demonstrated a significantly increased frequency of epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) patients with malignant pleural effusions (MPEs). The purpose of this study is to investigate the effect of first-line and second-line EGFR-tyrosine kinase inhibitors (TKIs) in the treatment of NSCLC with MPEs harboring exon 19 deletion and L858R mutation....
Topics
Join the communities discussing this publication.